ArticleClinical drug investigation2020
Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study.
Article in Clinical drug investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Therapeutic Enoxaparin Dosing in Obesity.The Annals of pharmacotherapy · 2025Pooled it
- A systematic review of therapeutic enoxaparin dosing in obesity.Journal of thrombosis and thrombolysis · 2024Pooled it
- Strategies involving low-molecular-weight heparin for the treatment and prevention of venous thromboembolism in patients with obesity: A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- The Role of Early Rehabilitation in Treatment of Acute Pulmonary Embolism-A Narrative Review.Journal of clinical medicine · 2025Review
- A Clinical Practice-Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin.Pharmacology research & perspectives · 2025Article
- Finding individualised treatment in obese needing enoxaparin (FIT ONE): a multicentre study of therapeutic enoxaparin and the role of anti-factor Xa monitoring.Journal of thrombosis and thrombolysis · 2025Article
- Does One Size Fit All? - Refining Parenteral Anticoagulant Therapy According to Body Weight.Arquivos brasileiros de cardiologia · 2025Article
- Use of Anticoagulant Therapy in Obese People: What is the Evidence for the Ideal Dose?Arquivos brasileiros de cardiologia · 2024Article
- Anticoagulation approach in morbid obesity: a comprehensive review on venous thromboembolism management.Frontiers in pharmacology · 2024Review
- Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021.Arquivos brasileiros de cardiologia · 2021 · on this mapArticle
- Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".Clinical drug investigation · 2020Article
- Response to Comment on: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".Clinical drug investigation · 2020Article
- Preparedness of pharmacists to respond to the emergency of the COVID-19 pandemic in Brazil: a comprehensive overview.Drugs & therapy perspectives : for rational drug selection and use · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnoxaparin is a low-molecular weight heparin (LMWH) commonly used for treatment of venous thromboembolism and acute coronary syndromes. The recommended dose for these conditions is weight-based (1 mg/kg) and doesn't require dose-capping. However, previous studies have shown that in those with a body mass index (BMI) > 40 kg/m
objectiveThis study investigated enoxaparin dosing in morbidly obese patients with a goal of identifying a dose with the greatest chance of producing favorable anti-factor Xa (anti-Xa) levels.
methodsThis retrospective cohort study by electronic chart review was used to record data of patients who received enoxaparin with anti-Xa level monitoring between 2012 and 2017. The primary outcome was the enoxaparin dose that results in a therapeutic anti-Xa level (0.5-1.0 IU/mL) among three BMI groups. Secondary outcomes were bleeding and thromboembolic events.
resultsTwo hundred forty-one patients were included in the study, and 132 achieved a therapeutic dose. For those with a BMI of 40-50 kg/m
conclusionStandard dosing of enoxaparin in morbidly obese patients will most likely lead to supratherapeutic anti-Xa levels and thus further investigation is warranted to better determine appropriate dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.